Patents by Inventor Yawen L. Chiang
Yawen L. Chiang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080213884Abstract: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector, therefore, a target tissue can be selectively treated.Type: ApplicationFiled: October 25, 2007Publication date: September 4, 2008Applicant: Cell Genesys, Inc.Inventors: Paul L. Hallenbeck, Yung-Nien Chang, Yawen L. Chiang
-
Patent number: 6761884Abstract: A vector, in particular a retroviral vector, which includes a heterologous or foreign gene and a gene encoding a negative selective marker. The negative selective marker enables one to kill cells which contain the gene encoding the negative selective marker, when a particular agent is administered to such cells.Type: GrantFiled: August 12, 1994Date of Patent: July 13, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Michael Blaese, W. French Anderson, Jeanne R. McLachlin, Yawen L. Chiang, Martin Eglitis
-
Publication number: 20030129175Abstract: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.Type: ApplicationFiled: December 19, 2002Publication date: July 10, 2003Inventors: Paul L. Hallenbeck, Yung-Nien Chang, Yawen L. Chiang
-
Publication number: 20030118570Abstract: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.Type: ApplicationFiled: December 19, 2002Publication date: June 26, 2003Inventors: Paul L. Hallenbeck, Yung-Nien Chang, Yawen L. Chiang
-
Publication number: 20030113296Abstract: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.Type: ApplicationFiled: December 19, 2002Publication date: June 19, 2003Inventors: Paul L. Hallenbeck, Yung-Nien Chang, Yawen L. Chiang
-
Patent number: 6551587Abstract: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector, therefore, a target tissue can be selectively treated.Type: GrantFiled: December 15, 1998Date of Patent: April 22, 2003Assignee: Genetic Therapy, Inc.Inventors: Paul L. Hallenbeck, Yung-Nien Chang, Yawen L. Chiang
-
Publication number: 20030012767Abstract: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that ihibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.Type: ApplicationFiled: December 15, 1998Publication date: January 16, 2003Inventors: PAUL L. HALLENBECK, YUNG-NIEN CHANG, YAWEN L. CHIANG
-
Publication number: 20020051767Abstract: A process for improving the treatment of a tumor by radiation therapy which comprises treating a tumor by radiation therapy wherein the cells of the tumor have been transduced with a polynucleotide encoding wild-type p53, such as, for example, by transducing the tumor cells with an adenoviral vector including a DNA sequence encoding wild-type p53. Such a combination treatment of the transduction of tumor cells with a polynucleotide encoding wild-type p53 and radiation therapy provides a more effective treatment than by using p53 gene therapy alone or radiation therapy alone.Type: ApplicationFiled: September 13, 1995Publication date: May 2, 2002Inventors: YAWEN L. CHIANG, ESTHER H. CHANG
-
Patent number: 5998205Abstract: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that ihibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.Type: GrantFiled: August 1, 1997Date of Patent: December 7, 1999Assignee: Genetic Therapy, Inc.Inventors: Paul L. Hallenbeck, Yung-Nien Chang, Yawen L. Chiang
-
Patent number: 5925345Abstract: A vector, in particular a retroviral vector, which includes a heterologous or foreign gene and a gene encoding a negative selective marker. The negative selective marker enables one to kill cells which contain the gene encoding the negative selective marker, when a particular agent is administered to such cells.Type: GrantFiled: May 25, 1995Date of Patent: July 20, 1999Assignees: Genetic Therapy, Inc., The United States of America as represented by the Department of Health and Human ServicesInventors: Michael Blaese, W. French Anderson, Jeanne R. McLachlin, Yawen L. Chiang, Martin Eglitis